Kwality Pharmaceuticals (539997) Q3 24/25 earnings summary

Executive summary

• Consolidated revenue rose 8% year-over-year to Rs 85.06 crores in Q3FY25, with EBITDA up 5% to Rs 18.2 crores and net profit up 11% to Rs 8.52 crores compared to Q3FY24.

• SFDA (Saudi Arabia) approval for general and beta injectables and 10 new oncology product approvals were secured, expanding presence in GCC, Middle East, and Europe.

• Preclinical trials for the first biosimilar Erythropoietin have commenced, following RCGM approval.

Financial highlights

• Standalone Q3FY25 revenue from operations: Rs 8,440.72 lakhs; total revenue: Rs 8,506.19 lakhs.

• Standalone net profit after tax for Q3FY25: Rs 853.89 lakhs, up from Rs 770.29 lakhs in Q3FY24.

• Consolidated Q3FY25 net profit: Rs 852.09 lakhs; total comprehensive income: Rs 847.56 lakhs.

• Basic and diluted EPS for Q3FY25: Rs 8.2 (consolidated), Rs 8.23 (standalone).

• EBITDA margin remained steady at approximately 22% for recent quarters.

Outlook and guidance

• Target to double revenues by FY26 from FY23 levels, maintaining sustainable EBITDA margins of 22-25%.